Tenaya Therapeutics

NEWS ALERT: Encouraging early data from Tenaya’s MyPEAK™-1 Phase 1b clinical trial for the treatment of MYBPC3-associated hypertrophic cardiomyopathy (#HCM). MyPEAK-1 is an on-going clinical trial evaluating the first gene therapy for the leading genetic cause of HCM to be assessed in humans. Learn more: bit.ly/4gHtv4x #GeneTherapy

Meet Gabe and his family. Gabe is a young boy who had a heart transplant for hypertropic cardiomyopathy (#HCM). Since his diagnosis as a newborn, Gabe’s mother, Brittni, has been working to raise awareness in her community about the genetic heart condition her son was born with. Learn more about Gabe and his family’s journey: https://bit.ly/4gvvOYk

Every year, our Tenaya Trees of Thankfulness grow with notes of gratitude, as we recognize the incredible impact of our team members. This season, we’re especially thankful for our amazing team, dedicated partners, and supportive community who make our work possible. Together, we’re #OneTenaya! #HeartDisease #GeneTherapy

At Tenaya, we have created proprietary in vitro and in vivo disease models and integrated them within our research organization. Our in vitro human iPSC-CM disease models allow us to simulate human diseases and enable high-throughput target identification and drug discovery. On the in vivo side, our dedicated pharmacology group has established many animal models of heart disease, allowing us to efficiently evaluate the impact of our developing therapies. Learn more about our science: https://bit.ly/4fdkUps #GeneTherapy #HeartDisease

NEWS ALERT: The first patient has been dosed in our TN-401 gene therapy in the RIDGE-1 Phase 1b clinical trial, marking a significant step forward in our journey to transform care for individuals living with PKP2-associated #ARVC. This milestone reflects our unwavering commitment to discover, develop and deliver potentially curative therapies that address the underlying drivers of #heartdisease. Read more: https://lnkd.in/eqfwvcQU #HCM #GeneTherapy #Biotech

#TeamTenaya recently hosted a safety contest that brought everyone together to refresh best practices through some friendly competition and teamwork. Keeping our work environment safe is our top priority! Check out some of the highlights of our time together. #TenayaTherapeutics #LabSafety #HeartDisease #HCM

#TeamTenaya recently attended the American Heart Association Scientific Sessions, where we joined a global community of researchers, scientists, and patients dedicated to advancing heart health. We're pushing boundaries to make transformative medicines a reality. Learn more about our science here: https://bit.ly/4enIrmB #AHA2024 #HeartDisease #HCM

Sharing your story can be a powerful way to reach and support others living with #ARVC and #HCM. At Tenaya, our Patient Advocacy team works to elevate the voices of individuals living with #cardiomyopathy. To learn more about how to engage with us, email patient.advocacy@tenayathera.com #GeneticHeartDisease #ARVD #PatientsFirst

A powerful story from Boston Children’s Hospital highlights Kiersten’s journey managing arrhythmogenic right ventricular cardiomyopathy (#ARVC), a rare and life-threatening condition often driven by PKP2 gene mutations. Her experience underscores the importance of specialized care and the critical need for genetic testing in guiding treatment for ARVC. #TeamTenaya is developing investigational therapies to change the treatment paradigm for heart disease. Our mission is to improve and extend the lives of millions of individuals and families fighting these debilitating diseases. Read Kiersten’s story here: https://bit.ly/3Cevo9C #HeartDisease #Cardiomyopathy #GeneTherapy

At Tenaya, we are researching gene therapies for genetic heart conditions, like #ARVC. Tenaya’s investigational gene therapy is intended to target muscle cells in the heart to treat the underlying genetic cause of ARVC. Learn more about TN-401 and how it works by watching the full video: https://bit.ly/47YvVIS #GeneTherapy #HeartDisease #Tenaya #ARVC #PKP2